Elie Dib

At Johns Hopkins, Elie Dib is a lecturer for the MS in Bioinformatics, MS in Biotechnology, and MS in Individualized Genomics and Health programs.

Dib is a board-certified hematologist-oncologist practicing in the Ann Arbor metro area in Michigan. He has a special interest in treating cancer with innovative therapies, including immunotherapy and targeted therapy, and his research interests are in immunogenomics.

Dib serves as a member of the National Cancer Institute’s Genitourinary Cancers Steering Committee and as the community vice chair of the Immuno-Oncology Committee for the Alliance for Clinical Trials in Oncology, Chicago, where he also co-chairs national clinical trials. Additionally, Dib serves on the national TAPUR molecular tumor board for the American Society of Clinical Oncology and is an associate editor for the ASCO Self Educational Program.
In his local community, Dib serves as associate program director for the Hematology Oncology Fellowship training program at St. Joseph Mercy Hospital in Ann Arbor. He is also a deputy principal investigator at the Michigan Cancer Research Consortium NCI Community Oncology Research Program.

His educational journey in hematology-oncology started at University of Rochester in New York. Dib then completed postgraduate education in cancer biology research at Harvard Medical School, with a focus on cancer immunotherapy and genomics. He also holds a Master of Science in individualized genomics and health from Johns Hopkins University.

Featured Works

• “Pertuzumab Plus Trastuzumab in Patients With Lung Cancer With ERBB2 Mutation or Amplification: Results From the Targeted Agent and Profiling Utilization Registry Study,” Apar K Ganti, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Elie G Dib…Richard L Schilsky, JCO Precision Oncology, June 14, 2023
• “Palbociclib in Patients With Non-Small-Cell Lung Cancer With CDKN2A Alterations: Results From the Targeted Agent and Profiling Utilization Registry Study,” Eugene R Ahn, Pam K Mangat, Elizabeth Garrett-Mayer, Susan Halabi, Elie G Dib…Richard L Schilsky, JCO Precision Oncology, June 25, 2020
• “Favorable Response to Pembrolizumab in a Patient With Metastatic Castration-Resistant Prostate Cancer Progressing While Receiving Enzalutamide,” Apar K Ganti, Michael Rothe, Pam K Mangat, Elizabeth Garrett-Mayer, Elie G Dib…Richard L Schilsky, Clinical Genitourinary Cancer, April 2019